Perioperative Smoking Cessation in Elderly Chinese Undergoing Spinal Fusion
Launched by THE SECOND HOSPITAL OF SHANDONG UNIVERSITY · Aug 28, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to help older Chinese patients stop smoking before and after spinal fusion surgery. Spinal fusion is a procedure that connects two or more bones in the spine to help with pain and improve movement. Because older patients often face more risks after surgery, the goal of this study is to create a special program that supports these patients in quitting smoking, which could lead to better recovery and fewer complications.
To be eligible for this study, participants need to be 65 years or older and planning to have spinal fusion surgery as part of an enhanced recovery after surgery (ERAS) program. They must also agree to take part in the study. Unfortunately, people who have had previous spinal surgery, certain spinal conditions, or who might struggle to understand the study will not be able to participate. Those who join can expect support and guidance tailored to help them quit smoking, which could improve their recovery experience after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients aged 65 years old or more;
- • 2. Patients who plan to undergo spinal fusion with ERAS program;
- • 3. Patients who agreed to participate in this study.
- Exclusion Criteria:
- • 1. Patients who cannot understand the study content or have difficulty communicating;
- • 2. Patients with a history of spinal fusion surgery;
- • 3. Patients with spinal fractures, spinal tumor, or spinal infections;
- • 4. Patients with congenital spinal deformity;
- • 5. Patients who were unable to complete at least 6 months of follow-up;
- • 6. Patients with incomplete clinical information.
About The Second Hospital Of Shandong University
The Second Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to improving patient outcomes by exploring new therapeutic interventions and enhancing existing treatment protocols. With a multidisciplinary approach and a robust infrastructure, the institution facilitates rigorous scientific inquiry while adhering to the highest ethical standards. The Second Hospital of Shandong University actively collaborates with researchers and healthcare professionals to contribute to the global body of medical knowledge and to ensure the delivery of safe and effective care to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported